Resyl

Quick links to important sections

Resyl

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Resyl

Property Description
Active ingredient Guaifenesin
Form Oral Liquid (Syrup or Solution)
Pharmacological class Expectorant / Mucoactive Agent
General purpose Relieving chest congestion
Origin Synthetic organic compound

What Type of Medicine is Resyl?

Resyl is an oral medicinal preparation classified as an Expectorant and a Mucoactive agent, containing the single active ingredient Guaifenesin. The preparation's identity is defined by this substance, which is a synthetic organic compound chemically known as Glyceryl guaiacolate. Guaifenesin is a standardized cold and cough remedy classified under ATC Code R05CA03. The medicine is most commonly available as a liquid, such as a Syrup or Solution, intended for oral intake. Guaifenesin is used for the symptomatic management of respiratory issues. While Resyl is typically a single-ingredient product, it may also be formulated as a combination product, such as Resyl plus, where Guaifenesin is paired with a secondary antitussive agent for a compound action.


Guaifenesin's General Purpose as an Expectorant

The general purpose of Resyl is to provide relief from the sensation of heavy chest congestion by helping the body manage thick respiratory mucus. As an expectorant, its primary function is achieved by significantly reducing the viscosity of tenacious secretions in the lower respiratory tract. This action helps to loosen phlegm and thin bronchial secretions. This physiological process essentially works to thin and hydrate the sticky mucus, enabling the body's natural defense mechanisms to clear the airways more effectively. This mechanism is intended to make a cough more productive, which is a step for relieving congestion and managing a typical, non-chronic cough associated with common cold symptoms. By facilitating expectoration, the medicine aids in clearing the lower respiratory passages.

What side effects are possible with Resyl?

Possible Side Effects and Safety Information

The safety profile of Resyl, which contains the expectorant Guaifenesin, is officially structured by regulatory documentation that categorizes known adverse reactions and necessary restrictions on use. These documented effects primarily involve specific physiological systems.

Most reported adverse reactions, such as nausea, vomiting, abdominal discomfort, headache, and dizziness, are classified in regulatory documents with a frequency of Not known. This indicates that while these effects have been reported through post-marketing surveillance, a precise incidence rate cannot be reliably estimated from the available data.


System-Organ Classes and Serious Reactions

Adverse effects are documented across several System-Organ Classes, including:

  • Gastrointestinal Disorders
  • Nervous System Disorders
  • Skin and Subcutaneous Tissue Disorders
  • Immune System Disorders

As a serious adverse reaction, the potential for anaphylactic reaction—a severe form of hypersensitivity—is officially recognized in regulatory safety reports. Additionally, effects on the Renal and Urinary Disorders class include reports of urolithiasis (kidney stone formation) associated with prolonged or chronic use.


Safety Restrictions and Special Considerations

Regulatory documents include high-level constraints defining the appropriate use of the medicine. The product is contraindicated in individuals with a known hypersensitivity to Guaifenesin or any of its inactive components. It is also noted as not intended for use in managing a persistent or chronic cough, as such conditions require further medical evaluation.

Cautionary statements also apply to specific populations. Use during pregnancy and lactation requires professional advice due to limited human data. Furthermore, caution is advised for patients with Porphyria, as the substance is possibly porphyrogenic.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Resyl (Guaifenesin) overdose strictly defines the documented manifestations and the required emergency response. Acute presentations are commonly observed in the gastrointestinal system, primarily involving nausea, vomiting, and abdominal discomfort. Regulatory documents also note transient central nervous system effects, such as drowsiness, following excessive ingestion.

A specific, severe outcome noted in prescribing information is the potential for the formation of renal calculi (kidney stones). This risk is associated with chronic, excessive consumption of the active substance over time rather than a single acute event.

Regulatory authorities mandate immediate action in any suspected overdose scenario. Users must seek medical help or contact a Poison Control Center right away. Urgent medical attention is specifically required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. The official treatment strategy for overdose is defined as strictly symptomatic and supportive, as regulatory documents confirm that no specific antidote is available for Guaifenesin. Management focuses on monitoring vital signs and fluid balance to support the individual during the acute phase.

Therapeutic Uses of Resyl

The primary therapeutic use of Resyl (Guaifenesin) is to provide supportive symptomatic relief for conditions involving mucus and congestion. The substance is used for the temporary relief of congested chests and coughs associated with the common cold.

Resyl is commonly used for managing symptom clusters related to heavy chest congestion and cough associated with acute episodes such as the common cold, influenza, and acute bronchitis. It may also be applied when supportive assistance is needed in managing persistent mucus accumulation in stable chronic respiratory conditions. This supportive relief contributes to easing the overall symptom burden.

The medication is relevant for easing challenging symptoms characterized by the presence of thick, tenacious secretions that are difficult for the patient to clear. It is applied across domains where additional symptomatic support is needed to address the symptoms of tightness or fullness caused by retained secretions. This supports the patient during difficult episodes by easing distress related to mucus clearance, contributing to functional stability.

Quick Fact: Relief for Congested Chests

The medication is commonly used to help with a cough that is associated with excessive phlegm where the primary focus is addressing symptoms related to heightened physiological activity caused by retained secretions.

Regulatory References

  1. Australian Therapeutic Goods Administration (TGA) monograph

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Resyl

Official eligibility for Resyl (Guaifenesin) is determined by regulatory agencies based on age, known allergies, organ function, and specific pre-existing conditions.

Eligibility Status Officially Documented Rules
Use is Established Adults and adolescents 12 years of age and over. Use is generally established for older adults.
Absolute Contraindication Patients with known hypersensitivity or allergy to Guaifenesin or any inactive ingredient must not use the medicine.
Pediatric Restrictions Use is not recommended for children under 4 years of age. Infants under 2 years must consult a physician, as safety and efficacy are not established in this age group. Use of extended-release formulations is generally restricted to ages 12 and over.
Conditional Use (Caution) Caution is advised in the presence of severe renal (kidney) impairment or severe hepatic (liver) impairment. Professional guidance is required for use during pregnancy (FDA Category C) and lactation.
Comorbidity Restriction A health professional must be consulted before use for a persistent or chronic cough (such as one associated with asthma or smoking) or a cough accompanied by excessive phlegm.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Resyl, containing the expectorant Guaifenesin, has a limited interaction profile documented in official regulatory sources. These interactions primarily involve a necessary restriction against co-administration with other cough and cold preparations, as well as documented interference with specific clinical laboratory tests.

Pharmacodynamic Restriction

Interacting Substance Category Interaction Restriction
Products containing Guaifenesin Co-administration is restricted to prevent unintentional double-dosing and potential excessive exposure. Many over-the-counter cough and cold medicines contain Guaifenesin, and combining them with Resyl is prohibited.

Drug-Laboratory Test Interference

Guaifenesin is documented to interact with certain colorimetric assays, which are analytical methods used to measure specific metabolites in the urine. This interaction is not a drug-drug interaction but a procedural constraint in clinical diagnostics.

Affected Laboratory Assay Documented Outcome
5-Hydroxyindoleacetic Acid (5-HIAA) Guaifenesin may interfere with the assay, potentially yielding falsely elevated results.
Vanillylmandelic Acid (VMA) The substance may also interfere with the VMA assay, leading to a risk of falsely increased values.

Overall Interaction Structure

Official regulatory labeling does not describe significant, clinically relevant interactions mediated by cytochrome P450 enzymes or drug transporters. Furthermore, regulatory documents do not impose mandatory timing rules for administration or list prohibitions regarding co-administration with specific foods, alcohol, or common herbal products. The regulatory profile is focused on managing the risk of excessive exposure from combination products and ensuring accurate laboratory results.

Mechanism of Action

Resyl (guaifenesin) exerts its action by modulating the physicochemical properties of respiratory tract secretions. The molecule is classified as a protussive or expectorant agent. Its primary mechanism involves stimulating and increasing the volume of serous secretions within the respiratory mucosal glands.

This glandular stimulation is mediated through an irritant effect on the gastric mucosa following oral administration, which triggers a reflex parasympathetic response. The efferent signal to the respiratory system, via the vagus nerve, causes a subsequent increase in the output of less viscous fluid from the submucosal glands lining the airways.

At the molecular level, this action is thought to directly and/or indirectly facilitate the release of fluid and electrolyte content into the tracheobronchial lumen. The net physiological consequence is a decrease in the viscosity and an increase in the clearance of the resultant airway secretions.

Dosage and Administration Information

How to Use Resyl: Official Administration Guidelines

The usage of Resyl (Guaifenesin) follows established administration protocols focusing on the approved dosage forms, frequency, and specific intake conditions.

Resyl is intended for oral administration only, regardless of whether the formulation is a liquid, syrup, or tablet. The active ingredient is available in two main formats, each with a distinct dosing schedule to be followed.


Labeled Dosing and Frequency

Formulation Type Adult Dosing (Age 12 and older) Frequency Maximum Daily Dose
Immediate-Release (IR) 200 mg to 400 mg per dose Every 4 hours (q4hr) Not to exceed 2400 mg
Extended-Release (ER) 600 mg to 1200 mg per dose Every 12 hours (q12hr) Not to exceed 2400 mg

Dosing for pediatric populations (ages 2 to under 12) requires reduced dose ranges and limits; use for children under 2 years must be directed by a healthcare professional.


Administration Requirements and Constraints

  • Fluid Intake: The medicine should be taken with a full glass of water. Intake with water is intended to support the mechanism of thinning bronchial secretions.
  • Food Relationship: Administration can occur without regard to the timing of meals.
  • Handling Constraints: Extended-release tablets must be swallowed whole. They are not to be crushed, chewed, or broken, as this action would compromise the integrity of the controlled-release mechanism built into the formulation.
  • Duration: Resyl is labeled for short-term use for acute symptoms. If symptoms persist for longer than seven days, use should be discontinued and professional consultation sought.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Resyl


Evidence for Use in Acute Chest Congestion

The primary evidence base for Resyl (Guaifenesin) comes from short-term randomized controlled trials (RCTs). These studies mainly included adults and adolescents experiencing acute symptoms from the common cold or acute bronchitis. These short-term trials were used in research examining how symptoms change over time during an acute episode.

In these studies, researchers often monitored patient-reported outcomes (PROs), which involve daily assessments of the patient's own experience of symptoms. These outcomes focused on outcomes related to physical discomfort, specifically tracking how patients perceived the thickness of their chest secretions and the frequency and intensity of their cough. Scientific analyses have noted that the findings were mixed and varied across studies, particularly when comparing the subjective reports from patients with the results of objective laboratory assessments.


Evidence for Managing Persistent Mucus in Chronic Conditions

Resyl was evaluated in studies for use in managing persistent mucus in stable, long-term respiratory conditions characterized by fluctuating or episodic manifestations like Chronic Bronchitis. The research base here includes longer-duration studies and observational settings evaluating daily-life functioning over extended periods.

These investigations were observed in study populations composed of adults with established chronic conditions. The research explored patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level over several weeks or months. Subsequent analyses noted that the findings of early research were sometimes limited or inconsistent regarding how symptoms evolved. More recent studies collected data on patterns related to symptom intensity or variability over longer periods.


What the Research Landscape Shows is Still Uncertain

The research highlights several key areas where certainty remains low or evidence is still emerging. One limitation is the heterogeneity of findings in acute trials, where the degree of subjective relief reported by patients does not always align with objective measurements of mucus changes, resulting in findings were mixed in some analyses. Similarly, the research focus on acute episodes shows that there are limited long-term data for the immediate-release form of the medicine. The evidence quality varies across studies, and the reliance on small sample sizes were modest in some earlier trials contributes to the overall recognized evidence gaps.

Key Studies & References

  1. A Study to Explore if Long-term Use of Mucinex Can Help With Symptoms in Patients With Stable Chronic Bronchitis (AHR CB) - ClinicalTrials.gov ID NCT05843669
  2. Guaifenesin Oral Drug Product Monograph (Immediate-Release) - DailyMed / FDA

Frequently Asked Questions (FAQ)

Common questions about Resyl (FAQ)

Q: Is Resyl a treatment for long-term conditions?

Official regulatory labeling indicates Resyl is intended for short-term use to manage acute symptoms of chest congestion. However, the active ingredient has been evaluated in research settings for its potential role in managing chronic symptoms, such as persistent mucus in conditions like chronic bronchitis. For any persistent or chronic cough, regulatory guidance states that medical consultation is necessary.

Q: Does Resyl need to be taken at a specific time of day?

No, the official labeling for Resyl does not require it to be taken at a specific time, such as morning or night. Dosing is prescribed to be taken as needed at regular intervals, such as every 4 hours for immediate-release (IR) formulations or every 12 hours for extended-release (ER) formulations.

Q: What happens when Resyl wears off?

The intended effect of Resyl is described as managing symptoms during the prescribed dosing interval (4 hours for IR or 12 hours for ER). The effect of the medicine is understood to wear off as the next scheduled dose time approaches. Official administration instructions emphasize that the maximum daily dosage limit must not be exceeded.

Q: What should I do if I think Resyl is not working for me?

Official safety warnings advise that use must be stopped and a healthcare professional consulted if cough symptoms persist for longer than seven days, if they return, or if they are accompanied by a fever, rash, or persistent headache. These criteria are used to determine when a condition may require further medical evaluation.

Q: Is Resyl considered safe for people with kidney problems?

Regulatory documents advise caution when Resyl is used by individuals with severe renal (kidney) impairment. This caution is generally related to the potential for excessive exposure and, in some cases of prolonged use, the risk of kidney stone formation (urolithiasis). In this case, professional guidance must be sought before use, as outlined in official documents.

Q: Can Resyl be used if I am breastfeeding?

Official guidance states that a health professional must be consulted before use if you are breastfeeding. This is because the available human data on whether the active ingredient passes into breast milk, and what effect it may have on the nursing infant, is limited.

Q: Is Resyl known to cause any skin reactions?

Yes, official adverse effect documents note that skin and subcutaneous tissue disorders have been reported. The product’s safety warnings also advise consulting a doctor if the cough occurs with a rash, which could be a sign of a serious condition or allergic reaction.

Q: Do I need to avoid alcohol completely while using Resyl?

General product warnings do not prohibit alcohol with single-ingredient Guaifenesin products. However, alcohol can potentially increase certain side effects like dizziness or drowsiness. It is important to check the labels of all medicines, as combination products may have strict warnings against alcohol use due to their added ingredients.

Q: What happens if I miss a time when I usually take Resyl?

Resyl is typically taken on an 'as needed' basis, and official labeling does not provide specific instructions for a missed dose. The general guidance for this type of medication is that if a dose is missed, it should not be doubled to make up for the omission, and the regulatory standard is not to take a double dose to compensate.

Q: Is it possible for Resyl to cause stomach upset?

Yes, regulatory documentation confirms that gastrointestinal side effects have been reported. These can include generalized abdominal discomfort, along with specific adverse reactions such as nausea and vomiting.

Q: Are there different strengths or forms of Resyl available?

The active ingredient, Guaifenesin, is manufactured in multiple forms and strengths. These include Immediate-Release (IR) tablets, Extended-Release (ER) tablets, oral solutions, and syrups. The different forms have distinct dosing schedules.

Q: Does Resyl have a 'Black Box' warning from the FDA?

Single-ingredient Guaifenesin products do not carry a Black Box Warning in their official labeling. These warnings are generally reserved for prescription medications that carry significant, life-threatening risks.

Q: Can people with liver issues use Resyl?

Official product information advises caution when the medicine is used by people with severe hepatic (liver) impairment. Official guidance notes that professional consultation is required before use for patients with liver disease.

Q: What population groups were included in the Resyl studies?

Clinical studies used to establish the safety and efficacy of Resyl have included healthy adults and adolescents (12 years and over). Research has also explored its use in children and in adults with chronic respiratory conditions, such as chronic bronchitis.

Q: What kind of monitoring is typically recommended for someone on Resyl?

Routine clinical monitoring is not generally specified for this type of over-the-counter medicine. However, the product labeling specifies conditions under which use must be discontinued and professional consultation sought, such as if the cough lasts more than seven days or is accompanied by other serious symptoms like a persistent fever or rash.

Q: Does Resyl contain gluten or common allergens?

While the active ingredient, Guaifenesin, does not contain gluten, specific product formulations can vary. The official labeling lists all inactive ingredients. For individuals with specific allergies, reviewing the inactive ingredients list on the product package is recommended.

Q: Is Resyl known to cause problems with sleep?

Guaifenesin is not typically known to cause insomnia. However, the official product safety information includes a warning to stop use and ask a doctor if nervousness or sleeplessness occur. This caution is most often noted with combination products that contain additional ingredients like decongestants.

Q: Can Resyl be taken with common pain relievers?

Yes, Resyl's active ingredient is frequently formulated in combination with pain relievers, such as acetaminophen, for multi-symptom relief. It is important to check the labels of all medicines being used to help prevent the accidental double-dosing of the pain reliever ingredient.

Q: Why are there warnings about combining Resyl with certain antidepressants?

Warnings about combining cough medicines with certain prescription antidepressants, like Monoamine Oxidase Inhibitors (MAOIs), mainly apply to combination products. This is due to the potential for drug interactions involving the cough suppressant ingredient (Dextromethorphan), which is sometimes paired with Guaifenesin.

Q: Does Resyl affect blood sugar levels?

The active ingredient, Guaifenesin, does not typically affect blood sugar. However, some liquid formulations may contain sugar or alcohol. Specific product lines are marketed as Sugar- and Alcohol-Free for patients with diabetes who need to strictly monitor their intake.

Q: Why is Resyl sometimes prescribed for uses other than the main one mentioned?

Official labeling is limited to use for acute chest congestion associated with the common cold. The medicine is sometimes discussed or evaluated in clinical research settings for non-labeled uses in chronic conditions, such as chronic bronchitis, where mucus hypersecretion is a symptom.

Q: Is Resyl available over the counter?

Yes, the active ingredient Guaifenesin is widely available as an Over-the-Counter (OTC) drug under an FDA Monograph for cough and cold. It is also available as a prescription drug, often in higher strengths or as a combination product with other prescription-only ingredients.

How should Resyl be stored and disposed of?

How to Store and Dispose of Resyl (Guaifenesin Oral Liquid)

Resyl, an oral liquid preparation, must be stored within a specific temperature range to maintain its stability, as defined by regulatory labeling. The medicine should be kept at Controlled Room Temperature, ideally between 20 C and 25 C (68 F and 77 F). It is a mandatory requirement to protect the product from freezing.

For container integrity, the medicine must remain in its original container and be kept tightly closed when not in use. As a universal child-safety rule, the product must be stored out of the sight and reach of children.

Disposal of unused or expired liquid must follow official guidelines. Do not dispose of the medicine down a sink or toilet unless explicitly instructed by a drug take-back program. Instead, discard the product according to the directions provided by a pharmacist or a local governmental waste disposal program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Resyl found in:

A-Z Index: